Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoioetic stem cell transplantation

Hematological Oncology

Volumn 26, Issue 3, 2008, Pages 123-130

  Baldanti, Fausto ^a   Lilleri, Daniele ^a   Gema, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Hematopoietic stem cell transplantation; Human cytomegalovirus; Pre emptive treatment; Viral load measurement

Indexed keywords

FOSCARNET; GANCICLOVIR; VIRUS DNA; VIRUS RNA; VIRUS ANTIGEN;

ANTIGENEMIA ASSAY; ANTIVIRAL THERAPY; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DRUG RESPONSE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INTERMETHOD COMPARISON; NONHUMAN; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RNA ANALYSIS; SENSITIVITY ANALYSIS; VIREMIA ASSAY; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS ISOLATION; VIRUS LOAD; BLOOD; CYTOMEGALOVIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; T LYMPHOCYTE; VIREMIA;

ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RNA, VIRAL; T-LYMPHOCYTES; VIRAL LOAD; VIREMIA;

EID: 54849417659     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.856     Document Type: Review

References (52)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Boeckh M, Ljungman P. Cytomegalovirus infection in bone marrow transplant recipients. In Transplant Infections. Bowden RA, Ljungman P, Paya C (eds). Lippincott-Raven: 1998: 215-227.
3. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65: 432-436.
4. Couriel D, Canosa J, Engler H, Collins A, Dumbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T- depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 347-353.
5. Zambelli A, Lilleri D, Pedrazzoli P, et al. Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 423-428.
6. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
7. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917-919.
8. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus Antigenemia. J Clin Microbiol 1992; 30: 1232-1237.
9. Gerna G, Zipeto D, Parea M, et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia. J Infect Dis 1991; 164: 488-498.
10. Gerna G, Baldanti F, Sarasini A, et al. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. Antimicrob Agents Chemother 1994; 38: 38-44.
11. Baldanti F, Zavattoni M, Sarasini A, Gatti M, Chezzi L, Gerna G. Comparative quantification of human cytomegalovirus DNA in blood of immunocompromised patients by PCR and Murex Hybrid CaptureTM System. Clin Diagn Virol 1997; 8: 159-165.
12. Hebart H, Gamer D, Loeffler J, et al. Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation. J Clin Microbiol 1998; 36: 1333-1337.
13. Kolberg J, Miner R, Hoo B, et al. Development of a branched DNA signal amplification assay to monitor patients on anti-CMV therapies. Biologicals 1996; 24: 216.
14. Gerna G, Baldanti F, Middeldorp JM, et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1999; 37: 902-911.
15. Churchill MA, Zaia JA, Forman SJ, Sheibani K, Azumi N, Blume KG. Quantitation of human cytomegalovirus DNA in lungs from bone marrow transplant recipients with interstitial pneumonia. J Infect Dis 1987; 155: 501-509.
16. Erice A, Borrell N, Li W, Miller WJ, Balfour HH Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1999; 178: 531-534.
17. Gerna G, Revello MG, Percivalle E, Zavattoni M, Parea M, Battaglia M. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 1990; 28: 2681-2688.
18. Gerna G, Zipeto D, Parea M, et al. Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. Mol Cell Probes 1991; 5: 365-374.
19. Grossi P, Minoli L, Percivalle E, Irish W, Vigano' M, Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995; 59: 847-851.
20. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenemia on patients' outcome. Br J Haematol 1994; 88: 64-71.
21. Gerna G, Sarasini A, Baldanti F, Percivalle E, Zella D, Revello MG. The Italian Foscarnet GID Study Group. Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Antiviral Res 1997; 34: 39-50.
22. Revello MG, Furione M, Zavattoni M, Gerna G. Human cytomegalovirus infection: diagnosis by antigen and DNA detection. Rev Med Microbiol 1994; 5: 265-276.
23. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999; 1: 165-178.
24. Baldanti F, Simoncini L, Sarasini A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998; 66: 324-329.
25. Baldanti F, Lilleri D, Campanini G, et al. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J Antimicrob Chemother 2004; 53: 536-539.
26. Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S, Gerna G. In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 1998; 101: 2686-2692.
27. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585-3589.
28. Limaye AP, Bowden RA, Myerson D, Boeckh M. Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997; 24: 830-835.
29. Gerna G, Zavattoni M, Baldanti F, et al. Human cytomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 1998; 65: 1378-1385.
30. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998; 36: 1113-1116.
31. Gerna G, Lilleri D, Zecca M, et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005; 90: 526-533.
32. Gerna G, Sarasini A, Lilleri D, et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 2003; 188: 1639-1647.
33. Gerna G, Furione M, Baldanti F, Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994; 32: 2709-2717.
34. Hebart H, Brugger W, Grigoleit U, et al. Risk for cytomegalovirus disase in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183-2185.
35. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
36. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survery of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763-767.
37. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
38. Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101: 5053-5060.
39. Lilleri D, Baldanti F, Gatti M, et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73: 412-418.
40. Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem cell transplantation compared with qualitative pp65 antigenemia. Blood 2007; 110: 2757-2760.
41. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cut-off for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant [E pub ahead of print] 2008; Jan 21.
42. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 7-13.
43. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-1380.
44. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
45. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
46. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
47. + T cells. Blood 2002; 100: 3297-3690.
48. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006; 108: 1406-1412.
49. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T-lymphocytes. Science 1996; 274: 94-96.
50. + T cell frequencies by flow cytometry: evidence for a novel antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99: 1739-1750.
51. Lozza L, Lilleri D, Percivalle E, et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005; 35: 1795-1804.
52. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.